1. Crestor (rosuvastatin calcium) is a new molecular entity approved by the FDA for sale in the United States by Astra Zeneca Pharmaceuticals on August 12, 2003. The molecule acts by reducing intestinal absorption of cholesterol and related phytosterols, and is thereby distinct relative to other statin therapies. The drug was approved for use in treating primary hypercholesterolemia and mixed dyslipidemia (by reducing total-C, LDL-C, and Apo B), and as an adjunct to other lipid-lowering treatments. It was thus approved for use alone or with other statins. A 2008 clinical trial revealed additional evidence supporting the superior performance of Crestor compared with a placebo treatment. Patent protection expires in January 2016. 2. Lovaza (omega-3-acid ethyl esters) is a new molecular entity introduced by Abbott labs and approved by the FDA on November 10, 2004. It was initially introduced under the trade name Omacor. Unlike statins, Lovaza is aimed at reducing tricylerides rather than low-density lipoproteins and may thus be combined with a statin as an adjunct therapy. Patent protection expired in September 2012. 3. Zetia (ezetimibe) is a new molecular entity introduced by Schering and approved by the FDA on October 25, 2002 for sale in the United States. The molecule acts by reducing intestinal absorption of cholesterol and related phytosterols, and is thus distinct from statins. The drug was initially approved for use in treating hypercholesterolemia for use alone or with other statins. In January 2008, a clinical trial found Zetia performed poorly compared with other therapies, and it was at that time recommended that Zetia not be prescribed except in cases for which all other cholesterol drugs had previously failed. Patent protection expires in April 2017. . The approval is for use of Altoprev for lowering cholesterol and LDL-C to target levels along with diet and exercise, to slow the progression of atherosclerosis in patients with coronary heart disease, and to reduce total-C, LDL-C, Apo B, and triclycerides and to increase HDL-C in patients with dyslipoproteinemia. The drug was found to outperform Mevacor (lovastatin). Altoprev is protected by patents though at least December 2017. 2. Lescol XL (extended-release Lescol) is a new dosage form and was approved by the FDA for sale in the United States by Novartis on October 6, 2000. Patent protection expired in 2012.
New drug combinations, January 2000-December 2010: 1. Advicor (Mevacor and extended-release Niacin) is a new drug combination approved by the FDA on December 17, 2001 for sale in the United States by Kos Pharmaceuticals. Advicor was approved for use in treating primary hypercholesterolemia and mixed dyslipidemia in two types of patients: a) those treated with lovastatin who require further triglyceride lowering or HDL raising who may benefit from adding niacin to their regimen, and b) patients previously treated with niacin who require further LDL lowering and may benefit from having lovastatin added to their regimen. Thus, Advicor was not approved as an initial therapy for lowering LDL levels. Moreover, in clinical trials, Advicor was found to perform no better than Mevacor as a first-line agent. 2. Pravigard PAC (Pravachol and aspirin) is a new drug combination approved by the FDA on June 24, 2003 for sale in the United States by Bristol Myers Squibb. 3. Vytorin (Zetia and Zocor) is a new drug combination approved by the FDA for use, along with diet or with other lipid-lowering treatments to reduce total C, LDL-C and raise HDL-C, on July 23, 2004 by MSP Singapore company, LLC. The drug combination was more effective at lowering lipids, but was also associated with more adverse events (both serious and leading to discontinuation) than either monotherapy. In January 2008, a completed clinical trial revealed Zetia, a component of Vytorin, performed poorly relative to other therapies. 4. Simcor (simvastatin and extended-release niacin) is a new drug combination approved by the FDA on February 15, 2008 for sale in the United States by Abbott Laboratories. Like Advicor, Simcor is approved only as a second-line treatment for cases in which the monotherapy is considered to be inadequate.
A.2 Data U.S. Prescriptions for Hypercholesterolemia and Dyslipidemia Therapies: Prescription data for U.S. medical practitioners and each of the products described above were obtained from the IMS Health Xponent database. IMS Health draws its prescription data from a large but non-random sample of over 70 percent of U.S. pharmacies. As of the time our data were assembled, Xponent included direct information from over 38,000 retail stores, including approximately 119 mail-service pharmacies and 820 long-term care facilities; this compares with a universe of approximately 57,000 retail pharmacies, 327 mail-service outlets, and 3,000 long-term care facilities. In addition to observing directly dispensed prescription volumes (or "sell-out") for each sample pharmacy, IMS Health observes prescription drug purchase volumes (or "sell-in") for the universe of U.S. pharmacies and drugs-that is, including both sample and non-sample stores. To correct for sampling error and to ensure the data are representative, IMS Health has applied a proprietary procedure that a) combines sell-in and sell-out data for sample pharmacies to determine what ratio of purchased product is actually dispensed for each drug and store, b) uses this ratio (or "projection factor"), appropriately weighted by store type and proximity, to estimate the dispensed volume by drug for any store reporting sell-in but not sell-out volumes. Importantly, this projection and weighting procedure applies only to strictly positive prescription levels, but does not apply to zeros, enabling us to accurately track the initial adoption of new products over time for each physician.
The data IMS Health provided include prescriptions by 280,622 unique U.S. physicians for each product in each month during January 2000 through December 2010. To avoid studying physicians specialized outside cardiovascular care, we restrict analysis to physicians that prescribe at least some cholesterol products. Specifically, for a physician to be included in the dataset, he or she needs to have written at least ten filled prescriptions for cholesterol therapies during the calendar year 2010. The data provide precise identifying information for each prescribing physician, including the unique, 11-digit American Medical Association Medical Education Number, the first name, last name, and middle name, and the fivedigit zipcode corresponding to the medical practice of the physician. From January 2006 through December 2010, the data provide additional detail regarding prescriptions: for each drug, a separate prescription count is observed for each of four payment methods, including Medicare Part D, Fee-for-Service Medicaid, cash, and commercial insurance. In the data, approximately half of dispensed prescriptions for cholesterol drugs correspond to individuals with commercial insurance; 34 percent obtain products through Medicare Part D, ten percent purchase medications with cash, and the remaining six percent are covered by Medicaid.
To prepare the data for analysis, we reshaped the files provided so that each row corresponds to a doctor-drug-month triplet. With guidance from IMS Health, zeros were explicitly introduced in this step for missing observations corresponding to existing products not associated with positive prescriptions in the IMS data. Starting in 2006, we aggregated prescriptions across methods of payment to arrive at a single number of prescriptions written by physician, drug, and month. We combined prescriptions for "Pravastatin" and "Pravastatin SOD", which are the same product, and did likewise for "Lovaza" and "Omacor", which are the same product. We dropped Baycol from the dataset. For some years, due to the projection calculation described above, the prescription variable was not a whole number; with guidance from IMS Health, we rounded the number of prescriptions to the nearest whole number. To abstract from physician entry during the sample period, we impose a sample restriction in addition to that described above: specifically, each physician included must prescribe at least ten cholesterol drugs during the calendar year 2000. Finally, we used information from the U.S. FDA to determine the approval date for each therapy. The first month after this date was determined to be the first month of a drug's market life in the United States. We created indicator variables for drugs that are new corresponding to the first six months of the drug's market life in the United States, and separately, to the first 24 months of the drug's market life in the United States. We created indicator variables for generic products lovastatin, pravastatin, and simvastatin.
Electronic Database Use for Hypercholesterolemia and Dyslipidemia Therapies, by U.S. Physicians: We obtained data on individual physicians' information access from the leading U.S. point-of-care medical applications firm. For each physician, we observe the corresponding initial database registration date; this is used to construct the indicator variable Z it that takes on a value of one for registered users, and that is otherwise zero. For each physician-product-month triplet, we also observe a proxy for the number of lookups completed. We use this proxy to construct a physician-specific indicator for database use that is equal to 1 if the doctor records at least one cholesterol drug lookup during the sample period, and that is otherwise zero. During January 2000 through December 2010, the share of sample physicians registered as database users rose from 0.003 to 0.451. Our analysis is thus based on a sample combining a) physicians that first registered during or before the sample period, and b) physicians that registered before the sample period, and c) physicians that never registered. Each physician is identified in the data by a unique, 11-digit American Medical Association Medical Education Number, first name, last name, middle name, and five-digit zipcode. These characteristics form the basis for a merge with the prescription information described above.
A.3 Endogenous Database Adoption: Instrumental Variables Results
One approach to handling the endogeneity of database adoption is to find an instrument that generates quasi-random variation in a physician's database adoption decision, and to estimate the impact of information access relying on variation in this instrument. We have considered three such instruments: 1) a measure of location-year specific hospital I.T. use from Dranove et al (2014), and 2) a measure of location-year specific high-speed internet penetration, and 3) the doctor-month specific share of other local physicians that have adopted the reference database; all three are factors that could influence doctors' database adoption decisions while being plausibly unrelated to choices over which anti-cholesterol drugs to prescribe. While we find that the first two instruments are only weak predictors of database adoption, resulting in second-stage estimates highly sensitive to small specification changes, the third instrument is a robust predictor of database adoption. We therefore reassess the results in Tables 4, 5 , and 6 using this third instrument. Estimates appear in Tables 7, 8 , and 9, respectively. The logic underlying the first stage is identical across all three specifications. Consider Table 5 : the first stage corresponding to a version of (6) that replaces η zt with η t is
where S z(i)t−1 is the share of physicians, excluding i, that are located in i's zipcode z(i) and are database users at t − 1.
49 The identification restriction is that the instrument is conditionally uncorrelated with the error term in (6):
Most explanations linking neighbors' database adoption decisions would suggest α > 0 in the first-stage specification above. One possible mechanism is that neighboring physicians are likely to share information about tools and techniques that improve professional performance; alternatively, physicians interacting locally may simply observe a peer accessing the database, and may decide to adopt on that basis. As discussed above, the reference firm's public statements indicate that such informal peer effects were the most important driver of database adoption among doctors during the sample period. Regarding excludability, it does not seem likely that the database adoption decisions of physicians neighboring i would directly affect i's own prescription decisions, as patient medical information is privacyprotected by law.
50
Whether the bias in our baseline estimates is upward or downward hinges on the rela-49 Notice that this instrument is not valid in the presence of zipcode-month fixed effects η zt . With η zt , identification through the instrument comes from comparing two doctors i and i in the same zipcode and month that have different adoption shares S z(i)t−1 and S z(i )t−1 . However, such a difference arises only when exactly one of the two has adopted the database. But in this case, the instrument for i directly reflects Z it−1 , which is correlated with Z it and thus also with the prescription outcome M it . We therefore replace the η zt (or η zj ) with η t (or η j ) in the instrumented specifications.
50 There are channels through which S z(i)t−1 could be correlated ε it in the second-stage equation. Changes in neighbors' database adoption could reflect changes in the proximity of their location to the technology frontier, possibly due to advertising; this could manifest itself not only in a high early rate of database adoption but also a high early rate of new drug adoption. Neighboring physicians that share information about database use could also share information about new drugs, affecting prescribing even if patientspecific details are not discussed. Such cases are better addressed by the baseline specification (6), which includes zipcode-month fixed effects that absorb local changes of these types.
tionship between the omitted factor and database adoption (Z it ). One possibility is that a physician makes an unobserved decision to move closer to the efficiency frontier by adopting new generic drugs quickly, prescribing them more often in place of a branded drug, and increasing the influence of patients' diverse characteristics on prescription choice-and that as a result of this unobserved decision, the doctor now finds it profitable to begin using the database to assist her increasingly complex prescription choices. This would suggest Cov(Z it , ε it ) ≥ 0 in (6) and a corresponding upward bias in our baseline estimate of β. On the other hand, if time-constrained physicians choose among multiple sources of drug information, those adopting the reference we consider (with Z it = 1) may do so at the expense of relying on a substitute resource that could affect prescribing similarly.
51 This would tend to result in Cov(Z it , ε it ) ≤ 0 in (6), placing downward pressure on the estimate of β.
The estimates in Table A .6 are largely in line with the latter interpretation. Based on our preferred second-stage estimates in column 1, database users are 8.0 percentage points more likely to begin prescribing a new generic within its initial year, relative to a non-user, with no significant effects among new branded drugs. The magnitude of the effect for generics is larger than in Table 4 , suggesting a bias toward zero for this coefficient; the coefficients for branded products are statistically indistinguishable. Columns 2 and 3 similarly suggest that the true impact of database adoption on diversity is an order of magnitude larger than in Table 5 . Column 4 likewise suggests that column 3 of Table 5 understates the impact of the database on generic prescribing by a factor of four for new generics (β 0 ) and a factor of ten for old generics (β 2 ).
52 However, database adopters are less likely to prescribe old branded drugs (β 3 < 0). Each table includes the first-stage estimates and reports the F statistic, which in every case is substantially higher than its weak-instrument threshold value.
Overall, the IV estimates reported in Table A .6 confirm a pattern of database impacts that is similar to the corresponding OLS estimates, but with larger estimated magnitudes. We view these as a set of robustness checks, with results that lend credibility both to the qualitative effects estimated above, and to a causal interpretation of these effects. Nevertheless, it is worth noting that our leave-out mean instrument relies on variation in group composition that in many applications leads to small-sample bias from weak instruments, and that could confound interpretation in certain cases (Angrist 2014). Regarding the former, we have confirmed the strength of the instrument, aided by the fact that the instrument varies over 13,000 zipcodes × 131 months = 1.7 million observations, across which there is sufficient heterogeneity for identification. Regarding the latter concern, that groups with high database adoption rates could also have different prescribing tendencies due to factors other than actual database access, three observations are useful. First, such an unobserved factor would need to cause a correlation between zipcodes' database adoption timing and increased generic prescribing in the absence of effects on brand-name drug adoption; second, provided this unobserved factor varies by zipcode-month, then it is reassuring that the baseline estimates including these fixed effects are qualitatively similar (Tables 4 and 5) ; third, we find that the results in Table A .6 are essentially unchanged when defining the instrument at a broader geographic unit (three digit zipcodes). Table  3 
All Physicians
Notes: * p < 0.10, ** p < 0.05, *** p < 0.01 and ª p < 0.11. This table provides least-squares estimates of a) equation (6) in columns 1-2, and b) equation (7) in column 3, for cholesterol drug prescriptions by U.S. physicians during January 2000 through December 2010 for all physicians. The dependent variable in column 1 captures the prescription diversity of physician i as the number of unique drugs j that are prescribed by i during month t . The dependent variable in column 2 is the prescription Herfindahl-Hirschman index for physician i in month t . The dependent variable in column 3 is an indicator for whether the doctor i prescribes drug j during month t. Database is the Drug Database and Use indicator variable described in Table  2 , and takes a value of 1 for a physician user with database access in month t ;; it is otherwise zero. All regressions include the cholesterol drug prescription volume for physician i in month t-1, physician-specific time trends, and physician and zipcode-month fixed effects;; column 3 also includes drug-month fixed effects. Standard errors clustered by zipcode appear below each point estimate. 
S. Physicians, Eventual Users, 2000-2010
Notes: * p < 0.10, ** p < 0.05, *** p < 0.01. This table provides least-squares estimates for a variant of (6) for cholesterol drug prescriptions by U.S. physicians during January 2000 to December 2010, and for the subset of physicians that eventually adopt and use the electronic reference to search for information about cholesterol drugs. The dependent variable in column 1 captures the prescription diversity of physician i as the number of unique drugs j that are prescribed by i during month t . The dependent variable in column 2 is the prescription Herfindahl-Hirschman index for physician i in month t . The dependent variable in column 3 is the generic share in prescriptions by physician i in month t . The specification replaces the Drug Database and Use indicator variable described in Table  2 with dummies for three years before adoption, two years before adoption, one year before adoption, the adoption year, one year after adoption, two years after adoption, and three or more years after adoption. All regressions include physician-specific time trends, physician and zipcode-month fixed effects, and the cholesterol drug prescription volume for physician i in month t -1. Standard errors clustered by zipcode appear below each point estimate. 
Eventual users

Eventual adopters
Notes: * p < 0.10, ** p < 0.05, *** p < 0.01. This table provides least-squares estimates of a variant of a) equation (5) for U.S. physicians' prescription of twelve cholesterol drugs first approved for U.S. sale during January 2000-December 2008 (Table  1) in column 1, and b) equation (6) for cholesterol drug prescriptions by U.S. physicians during January 2000 through December 2010 in columns 2-3. Doctors are included if they eventually adopt the electronic reference;; they need not have used it to search for information about cholesterol drugs. The dependent variable in column 1 captures the time lapse between FDA approval of drug j and physician i 's initial prescription of it, taking a value of 1 if initial prescription occurs within a year of FDA approval. The dependent variable in column 2 captures the prescription diversity of physician i as the number of unique drugs j that are prescribed by i during month t. The dependent variable in column 3 is the prescription Herfindahl-Hirschman index for physician i in month t. Database is the Drug Database and Use indicator variable described in Table  2 , and takes a value of 1 for a physician user with database access at the time drug j receives FDA approval. Generic indicates the products pravastatin, lovastatin, and simvastatin. Low, medium, and intense usage denote non-overlapping categories of physicians who, conditional on adoption, use the database to look up cholesterol drugs to differing extents;; the usage proxy is zero for low-intensity users, between zero and 14 for medium-intensity users, and above 14 for high-intensity users. All regressions include physician fixed effects the cholesterol drug prescription volume for physician i in the month prior to drug j's introduction;; column 1 includes zipcode-drug fixed effects and columns 2-3 include zipcode-month fixed effects and doctor-specific time trends. Standard errors clustered by zipcode appear Notes: * p < 0.10, ** p < 0.05, *** p < 0.01. This table provides least-squares estimates for a variant of (7) for the subset of physicians that eventually adopt the drug reference;; the specification is as described in Table  5 , column 3, but considers differences in the intensity of database use. Low, medium, and intense usage denote non-overlapping categories of physicians who, conditional on adoption, use the database to look up cholesterol drugs to differing extents;; the usage proxy is zero for low-intensity users, between zero and 14 for medium-intensity users, and above 14 for high-intensity users. (Table  1) in column 1, b) equation (6) in columns 2-3, and c) equation (7) in column 4. Dependent and independent variables are as described in Table  4 (column 1) and Table  2 , and takes a value of 1 for a physician user with database access at the time drug j receives FDA approval. Generic indicates the products pravastatin, lovastatin, and simvastatin. Estimates are presented for two subsamples: physicians located in states with active mandatory substitution laws (column 1) in the initial period and those without such laws (column 2);; the full-sample results in column 3 include interactions with an indicator for whether physician i's state has an active mandatory substitution law. Regressions include drug and physician fixed effects, as well as the cholesterol drug prescription volume for doctor i in the month prior to drug j's introduction. Standard errors clustered by zipcode appear below each point estimate.
Mandatory Substitution Law
Indicator for prescription within first year of drug introduction Notes: * p < 0.10, ** p < 0.05, *** p < 0.01. This table provides least-squares estimates for (5) and a variant thereof. The binary dependent variable captures the time lapse between FDA approval of drug j and physician i's initial prescription of it, taking a value of 1 if initial prescription occurs within a year of FDA approval;; specification are included for the subset of physicians that eventually adopt and use the electronic reference to search for information about cholesterol drugs. Database is the Drug Database and Use indicator variable described in Table  2 , and takes a value of 1 for a physician user with database access at the time drug j receives FDA approval. Generic indicates the products pravastatin, lovastatin, and simvastatin. Estimates in columns 1 and 2 are for subsamples: High includes all physicians in U.S. 4-digit zipcodes that are in the top five percent based on the number of USPTO medical patents granted (column 1), Low includes those in the bottom five percent (column 2). Full-sample results include interactions with indicators for High and Low medical patenting (column 3 ) and the log number of medical patents (column 4). All regressions include drug and physician fixed effects, as well as the cholesterol drug prescription volume for doctor i in the month prior to drug j's introduction. Standard errors clustered by zipcode appear below each point estimate.
Medical Patents
Indicator for prescription within first year of drug introduction
Eventual users
Database i = 0 
